[go: up one dir, main page]

MX336067B - Celula madre para uso terapeutico, la cual se deriva de monocito humano y metodo para inducir la misma. - Google Patents

Celula madre para uso terapeutico, la cual se deriva de monocito humano y metodo para inducir la misma.

Info

Publication number
MX336067B
MX336067B MX2011005480A MX2011005480A MX336067B MX 336067 B MX336067 B MX 336067B MX 2011005480 A MX2011005480 A MX 2011005480A MX 2011005480 A MX2011005480 A MX 2011005480A MX 336067 B MX336067 B MX 336067B
Authority
MX
Mexico
Prior art keywords
stem cell
monocyte
inducing
derived
therapeutic use
Prior art date
Application number
MX2011005480A
Other languages
English (en)
Other versions
MX2011005480A (es
Inventor
Hironobu Ishiyama
Hisanobu Hirano
Yasushi Ohkubo
Kenjiro Sasaki
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of MX2011005480A publication Critical patent/MX2011005480A/es
Publication of MX336067B publication Critical patent/MX336067B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/76—Undefined extracts from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

La presente invención se refiere a células madre obtenidas cultivando monocitos en presencia de (i) M-CSF y (ii) por lo menos un miembro seleccionado del grupo que consiste de un gangliósido y un extracto soluble en agua derivado de plantas, desdiferenciando de esta manera los monocitos; un agente terapéutico para tratar células, tejidos u órganos dañados; un agente de fármaco para células; un método para producir células madre; un medio de cultivo para desdiferenciar monocitos; un agente inductor de desdiferenciación; un kit de fármaco para células; un kit para producir células desdiferenciadas; y una composición farmacéutica.
MX2011005480A 2008-11-25 2009-11-19 Celula madre para uso terapeutico, la cual se deriva de monocito humano y metodo para inducir la misma. MX336067B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008299359 2008-11-25
PCT/JP2009/069648 WO2010061781A1 (ja) 2008-11-25 2009-11-19 ヒト単球由来治療用幹細胞およびその誘導方法

Publications (2)

Publication Number Publication Date
MX2011005480A MX2011005480A (es) 2011-06-20
MX336067B true MX336067B (es) 2016-01-06

Family

ID=42225657

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011005480A MX336067B (es) 2008-11-25 2009-11-19 Celula madre para uso terapeutico, la cual se deriva de monocito humano y metodo para inducir la misma.

Country Status (17)

Country Link
US (2) US9169463B2 (es)
EP (1) EP2365061A4 (es)
JP (1) JP5800505B2 (es)
KR (1) KR101682731B1 (es)
CN (1) CN102245757B (es)
AR (1) AR074406A1 (es)
AU (1) AU2009320881B2 (es)
BR (1) BRPI0921371A2 (es)
CA (3) CA2744289A1 (es)
CO (1) CO6341484A2 (es)
IL (1) IL212638A (es)
MX (1) MX336067B (es)
RU (1) RU2573906C2 (es)
TW (1) TWI539000B (es)
UA (1) UA110691C2 (es)
WO (1) WO2010061781A1 (es)
ZA (1) ZA201103268B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102399741A (zh) * 2010-09-19 2012-04-04 林雄斌 逆向分化体细胞产生造血干细胞的培养液、方法及用途
EP3524254A4 (en) * 2016-09-14 2020-11-11 Tes Holdings Co., Ltd. LIN28A ACTIVATOR AND USE OF IT
CN107904202B (zh) * 2017-11-22 2018-11-20 北京恩诺生物科技有限公司 一种制备多能干细胞样细胞的方法、组合物和应用
JP6375076B1 (ja) * 2018-02-19 2018-08-15 株式会社 バイオミメティクスシンパシーズ 間葉系幹細胞を用いたアトピー性皮膚炎治療における治療効果予測判定法
JP6574292B2 (ja) * 2018-07-21 2019-09-11 株式会社 バイオミメティクスシンパシーズ 間葉系幹細胞を用いたアトピー性皮膚炎治療における治療効果予測判定法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778787A (en) * 1985-12-20 1988-10-18 Trustees Of Boston University Method for treatment of angina and myocardial infarctions with omental lipids
US5272138A (en) 1988-02-12 1993-12-21 The Biomembrane Institute Naturally occurring gangliosides containing de-N-acetyl-sialic acid and their applications as modifiers of cell physiology
US6084060A (en) * 1996-12-09 2000-07-04 Imclone Systems Incorporated Composition and method for preserving progenitor cells
DE19651443A1 (de) * 1996-12-11 1998-06-18 Hoechst Ag Selbstverstärkende, pharmakologisch kontrollierbare Expressionssysteme
EP0893493A3 (de) * 1997-07-21 2002-12-04 Aventis Pharma Deutschland GmbH Genetisch veränderte Zellen und deren Verwendung in der Prophylaxe oder Therapie von Erkrankungen
US20030157113A1 (en) * 1999-12-28 2003-08-21 Terman David S. Compositions and methods for treatment of neoplastic disease
TWI288779B (en) * 2002-03-28 2007-10-21 Blasticon Biotech Forschung Dedifferentiated, programmable stem cells of monocytic origin, and their production and use
DE10214095C1 (de) * 2002-03-28 2003-09-25 Bernd Karl Friedrich Kremer Dedifferenzierte, programmierbare Stammzellen monozytären Ursprungs, sowie deren Herstellung und Verwendung
BRPI0408829A (pt) 2003-03-27 2006-04-04 Janssen Pharmaceutica Nv uso de eritropoietina em recuperação de acidente vascular cerebral
KR20110116225A (ko) * 2003-12-02 2011-10-25 셀진 코포레이션 혈색소병증　및　빈혈의　치료　및　관리를　위한　방법및　조성물
US20050260748A1 (en) * 2004-02-27 2005-11-24 Michigan State University Adult stem cells and uses thereof
EP2118269B1 (en) 2006-12-29 2013-03-13 Dow AgroSciences LLC In vitro methods for the induction and maintenance of plant cell lines as single suspension cells with intact cell walls, and transformation thereof

Also Published As

Publication number Publication date
US9169463B2 (en) 2015-10-27
CN102245757B (zh) 2014-11-26
CA2977823A1 (en) 2010-06-03
IL212638A (en) 2017-08-31
IL212638A0 (en) 2011-07-31
RU2573906C2 (ru) 2016-01-27
EP2365061A1 (en) 2011-09-14
MX2011005480A (es) 2011-06-20
KR20110094084A (ko) 2011-08-19
UA110691C2 (uk) 2016-02-10
TW201024415A (en) 2010-07-01
WO2010061781A1 (ja) 2010-06-03
KR101682731B1 (ko) 2016-12-05
JP5800505B2 (ja) 2015-10-28
CN102245757A (zh) 2011-11-16
US20160008434A1 (en) 2016-01-14
CA2744289A1 (en) 2010-06-03
TWI539000B (zh) 2016-06-21
RU2011126165A (ru) 2013-01-10
US20110223143A1 (en) 2011-09-15
JPWO2010061781A1 (ja) 2012-04-26
AU2009320881B2 (en) 2015-01-22
CO6341484A2 (es) 2011-11-21
AU2009320881A1 (en) 2010-06-03
ZA201103268B (en) 2012-07-25
AR074406A1 (es) 2011-01-12
BRPI0921371A2 (pt) 2014-11-18
EP2365061A4 (en) 2013-03-13
CA2977820A1 (en) 2010-06-03

Similar Documents

Publication Publication Date Title
BRPI0516969A (pt) método de preparar uma composição terapêutica, composição terapêutica, e, método de tratar um paciente humano sofrendo de hematopoiese deficiente
ES2572214T3 (es) Métodos para expansión celular y usos de células y medios acondicionados producidos de este modo para terapia
MX353245B (es) Metodos para reprogramar células y sus usos.
NZ609731A (en) Compositions of adult organ stem cells and uses thereof
WO2008137641A3 (en) Ex vivo expansion of human hematopoietic stem cells
WO2008056368A3 (en) Use of ex-vivo cultured hematopoietic cells for treatment of peripheral vascular diseases
BR0210599A (pt) Uso de monóxido de carbono, método para manutenção de uma célula animal in vitro, artigo de manufatura, bem como meio celular estéril
NZ593364A (en) Pharmaceutical preparation comprising supernatant of blood mononuclear cell culture
WO2007120811A3 (en) Hemangio-colony forming cells
BRPI0919804A8 (pt) Métodos e composição para o tratamento de problemas dermatológicos e/ou condições de cabelo
GB2434157A (en) Platelets from stem cells
WO2011082038A3 (en) Improved reprogramming compositions
WO2010124142A3 (en) Cell compositions derived from dedifferentiated reprogrammed cells
BRPI0718114A2 (pt) método para estimular a produção de fator de crescimento por células de sangue de cordão umbilical humano, método in vitro para expandir células de sangue de cordão umbilical humano, e, método para melhorar sobrevivência e crescimento de células de sangue de cordão umbilical humano transplantadas em um indivíduo
WO2010062911A3 (en) Compositions and methods of functionally enhanced in vitro cell culture system
MY170013A (en) Methods and compositions for enhancing stem cell mobilization
MX2009004776A (es) Celulas madre mesenquimaticas derivadas de medula osea como una fuente de progenitores neurales.
WO2009151907A3 (en) Compositions and methods for using cells to treat heart tissue
MX336067B (es) Celula madre para uso terapeutico, la cual se deriva de monocito humano y metodo para inducir la misma.
WO2011043629A3 (ko) 인간 지방 줄기세포의 고활성을 유도하는 방법 및 배지
PL1970068T3 (pl) Naprawa tkanek z wykorzystaniem komórek multipotencjalnych
MX2016005824A (es) Metodo de cultivo celular.
CL2010000774A1 (es) Medio para el cultivo de celulas de mamiferos que comprende ademas de los nutrientes habituales de los medios de cultivo basales para cultivo de celulas de mamiferos, sobrenadante de la fraccion ii+iii del plasma humano segun el metodo de cohn; procedimiento de preparacion; y su uso.
AR046123A1 (es) Aislamiento de celulas simil-celulas madre, uso de las mismas
BR112012022238A2 (pt) pele artificial